106
|
319
|
7chgA |
The structure of human pregnane x receptor in complex with an src-1 coactivator peptide and a limonoid compound |
96
|
244
|
7nelA |
Er-prs*(+) (y537s) in complex with estradiol and src-2 coactivator peptide |
87
|
237
|
7ndoA |
Er-prs*(-) (l536s, l372r) in complex with raloxifene |
97
|
243
|
7nfbA |
Er-prs*(+) (y537s) in complex with genistein and src-2 coactivator peptide |
99
|
293
|
7n2aA |
Human pxr lbd bound to compound 2 |
108
|
269
|
7e5iA |
Human ppar alpha ligand binding domain in complex with aphm6 obtained by soaking |
110
|
269
|
7e5gA |
Human ppar alpha ligand binding domain in complex with yn4pai obtained by soaking |
110
|
275
|
7e0aA |
X-ray structure of human ppargamma ligand binding domain-saroglitazar co-crystals obtained by co-crystallization |
110
|
269
|
7e5fA |
Human ppar alpha ligand binding domain in complex with tipp703 obtained by soaking |
109
|
269
|
7e5hA |
Human ppar alpha ligand binding domain in complex with aphm6 obtained by cocrystallization |
104
|
274
|
7cxhA |
The ligand-free structure of human ppargamma lbd q286e mutant in the presence of the src-1 coactivator peptide |
98
|
273
|
7cxkA |
The ligand-free structure of human ppargamma lbd r288h mutant in the presence of the src-1 coactivator peptide |
94
|
270
|
7cxjA |
The ligand-free structure of human ppargamma lbd r288c mutant in the presence of the src-1 coactivator peptide |
99
|
273
|
7cxeA |
The ligand-free structure of human ppargamma lbd r280c mutant |
92
|
271
|
7cxlA |
The ligand-free structure of human ppargamma lbd s289c mutant in the presence of the src-1 coactivator peptide |
103
|
272
|
7cxfA |
The ligand-free structure of human ppargamma lbd c285y mutant in the presence of the src-1 coactivator peptide |
101
|
273
|
7cxgA |
The ligand-free structure of human ppargamma lbd q286e mutant |
96
|
271
|
7cxiA |
The ligand-free structure of human ppargamma lbd f287y mutant in the presence of the src-1 coactivator peptide |
87
|
298
|
7bo6A |
Vdr complex with lca derivative |
85
|
231
|
7bk4A |
Crystal structure of rxralpha ligand binding domain in complex with a fragment of the tif2 coactivator |
95
|
300
|
7b39A |
Allene-based design of a noncalcemic vitamin d receptor agonist |
86
|
233
|
7apoA |
Crystal structure of raralpha ligand binding domain in complex with a fragment of the tif2 coactivator |
94
|
241
|
7aosB |
Crystal structure of the raralpha/rxralpha ligand binding domain heterodimer in complex with a fragment of src1 coactivator |
78
|
232
|
7aosA |
Crystal structure of the raralpha/rxralpha ligand binding domain heterodimer in complex with a fragment of src1 coactivator |
91
|
275
|
7a7hA |
Crystal structure of ppargamma in complex with compound tk90 |
88
|
249
|
7rs7A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-30 |
88
|
240
|
7rrxA |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-19 |
88
|
252
|
7rs2A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-23 |
91
|
247
|
7rs4A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-8 |
85
|
239
|
7rs8A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-16 |
91
|
242
|
7rs0A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-18 |
85
|
241
|
7rrzA |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-30 |
87
|
242
|
7rs3A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-29 |
90
|
243
|
7rs9A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-25 |
88
|
244
|
7rryA |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-20 |
86
|
242
|
7rs1A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-21 |
84
|
240
|
7rs8D |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-16 |
96
|
293
|
7riuA |
Human pxr lbd bound to gsk002 |
95
|
292
|
7rioA |
Human pxr lbd bound to gsk003 |
100
|
293
|
7rivA |
Human pxr lbd bound to gsk001 |
98
|
298
|
7oy4A |
Vdr complex of a side-chain hydroxylated derivatives of lithocholic acid |
96
|
297
|
7oxzA |
Vdr complex with a side-chain hydroxylated derivative of lithocholic acid |
68
|
231
|
7e2eA |
Crystal structure of the estrogen-related receptor alpha (erralpha) ligand-binding domain (lbd) in complex with an agonist ds45500853 and a pgc-1alpha peptide |
79
|
240
|
7msaA |
Gdc-9545 in complex with estrogen receptor alpha |
95
|
242
|
7np6A |
Ror(gamma)t ligand binding domain in complex with allosteric ligand fm257 |
99
|
242
|
7necA |
Ror(gamma)t ligand binding domain in complex with allosteric ligand fm217 |
91
|
240
|
7npcA |
Ror(gamma)t ligand binding domain in complex with allosteric ligand fm156 |
97
|
242
|
7np5A |
Ror(gamma)t ligand binding domain in complex with allosteric ligand fm216 |
103
|
269
|
7c6qA |
Novel natural pparalpha agonist with a unique binding mode |
89
|
238
|
7khtA |
The acyl chains of phosphoinositide pip3 alter the structure and function of nuclear receptor steroidogenic factor-1 (sf-1) |